Search

Your search keyword '"Forstner, B."' showing total 3 results
Start Over Author "Forstner, B." Topic antimetabolites, antineoplastic
3 results on '"Forstner, B."'

1. Cross-resistance of 5-fluorouracil-resistant colon carcinoma in vitro.

Author

Ratzenboeck IE, Bartl B, Forstner B, Kalipciyan M, Steger GG, and Mader RM

Subjects
Cell Line, Tumor, Cell Survival drug effects, Drug Resistance, Neoplasm, Humans, Antimetabolites, Antineoplastic pharmacology, Colonic Neoplasms drug therapy, Fluorouracil pharmacology
Published
2011

2. Phase II trial of gemcitabine in advanced non-small-cell lung cancer.

Author

Malayeri R, Ulsperger E, Baumgartner G, Forstner B, Aigner K, Hubner M, Kummer F, Krajnik G, Zöchbauer S, Krejcy K, Huber H, and Pirker R

Subjects
Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic adverse effects, Austria, Carcinoma, Non-Small-Cell Lung pathology, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Palliative Care, Treatment Outcome, Gemcitabine, Antimetabolites, Antineoplastic administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Deoxycytidine analogs & derivatives, Lung Neoplasms drug therapy
Abstract

Gemcitabine has shown activity in different solid tumors. In the present study we have evaluated its efficacy in 32 patients with advanced non-small-cell lung cancer in a phase II trial. Gemcitabine (1250 mg/m2) was given intravenously as a 30-minute infusion on days 1, 8 and 15. Cycles were repeated every 4 weeks. Twenty-nine patients were evaluable for response and all patients for toxicity. Partial remissions and stable disease were seen in 4 (14%) and 13 (45%) patients, respectively. Improvement of symptoms occurred in 54% of the patients. Side effects were mild and included predominantly leukopenia and thrombocytopenia. In conclusion, gemcitabine is active and well tolerated in patients with advanced non-small-cell lung cancer.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results